Study #2024-0173
Phase Ib study of AlpeliSib with PEmbroLizumab in patients with mEtastatic breast caNcer or melanomA (SELENA)
MD Anderson Study Status
Enrolling
Treatment Agent
Alpelisib + Pembrolizumab
Description
To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
Study phase:
Physician name:
Ecaterina Ileana Dumbrava
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-909-0599
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.